BOTHELL, Wash.--(BUSINESS WIRE)--April 28, 2006--Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS - News) today announced that it has entered into purchase agreements for the sale of approximately $30.6 million of its common stock in a registered direct offering. Under the terms of the financing, the Company will sell approximately 6.1 million shares of Sonus common stock at $5.00 per share to a select group of new and current institutional investors, led by Federated Kaufmann Funds. The transaction is expected to close on May 2, 2006, subject to customary closing conditions. All of the shares of common stock are being offered pursuant to an effective registration statement previously filed with the Securities and Exchange Commission.
